04 · 21 proprietary layers
Layer 16 of 21 · Action and continuity
TrialGraph Clinical trial matching and prioritisation.
Why it's needed
Which clinical trials may be relevant for further review based on the case and available trial criteria?
What it draws on
4 of 8 evidence domains.
What it produces
Potential trial matches and a rationale for review, if the product supports that output.
Why it's essential
Layer 16 of 21.
1 · What it does
What TrialGraph does
Clinical trials can offer access to treatments under investigation, but finding relevant ones is difficult. TrialGraph is intended to identify trials that may be relevant to the case for the treating team to review, with the reasons for each match.
2 · Scientific question
The question it addresses
Which clinical trials may be relevant for further review based on the case and available trial criteria?
Intended function
Explain how disease, biomarker, location and eligibility information are compared where supported.
3 · Data inputs and required context
What it draws on
- 01 Molecular & genomic
- 03 Clinical context
- 06 Treatment exposure
- 08 Evidence ecosystem
Diagnosis, biomarkers, prior therapy and location, compared against trial criteria.
4 · Scientific basis
The science behind it
Scientific basis
Trial matching compares structured case features with eligibility criteria published in trial registries. Criteria are often free text, incomplete or subject to change, and final eligibility is always determined by the trial team after screening.
5 · Output and evidence sources
What it produces
Main output
Potential trial matches and a rationale for review, if the product supports that output.
Output type
- Evidence-linked interpretation. Connects a finding to published or curated evidence, which has a source and a date.
6 · Why it\u2019s essential
How it powers the Twin
Produces the clinical-trial-matches section of the report. Trial intelligence is a Twin capability, not a separate product.
Report section
Capability
ExploreReview treatment-relevant evidence, resistance-related findings and potential trial matches.
7 · Why it\u2019s needed
What it changes — for doctors, patients and researchers
Clinicians
A prioritised list of trials to review, with match rationale and known gaps.
Doctor & Clinical TeamPatients & caregivers
A potential match is a starting point for a conversation, not an offer of a place.
Patient & Caregiver8 · Dependencies and limitations
Limitations
- A potential match is not confirmed eligibility, enrolment, slot availability or a guarantee of sponsor acceptance.
- Registry information can be out of date, and recruitment status changes.
9 · Review and uncertainty
How the output is handled
Output status
An AI-assisted analytical output presented as structured findings for clinician review. It becomes part of a report only after the treating oncologist has reviewed and signed it.
How uncertainty is communicated
Each match shows the criteria met, the criteria unknown and the criteria that need checking.
10 · Claim boundary
What this layer does not establish
It does not confirm that a patient is eligible for, or will be accepted into, any trial.
The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.
KPCIRC sign-off process